363 related articles for article (PubMed ID: 20846318)
1. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model.
Patel JJ; Mendes MA; Bounthavong M; Christopher ML; Boggie D; Morreale AP
J Eval Clin Pract; 2012 Apr; 18(2):247-55. PubMed ID: 20846318
[TBL] [Abstract][Full Text] [Related]
2. [Economic evaluation of bevacizumab versus ranibizumab in neovascular age-related macular degeneration].
Li H; Li X; Xie F
Zhonghua Yan Ke Za Zhi; 2014 Jun; 50(6):426-33. PubMed ID: 25241975
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.
Hernandez-Pastor LJ; Ortega A; Garcia-Layana A; Giraldez J
Clin Ther; 2008 Dec; 30(12):2436-51. PubMed ID: 19167602
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration.
Stein JD; Newman-Casey PA; Mrinalini T; Lee PP; Hutton DW
Ophthalmology; 2014 Apr; 121(4):936-45. PubMed ID: 24405740
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration (an American Ophthalmological Society thesis).
Stein JD; Newman-Casey PA; Mrinalini T; Lee PP; Hutton DW
Trans Am Ophthalmol Soc; 2013 Sep; 111():56-69. PubMed ID: 24167325
[TBL] [Abstract][Full Text] [Related]
6. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
Brown MM; Brown GC; Brown HC; Peet J
Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.
Dakin HA; Wordsworth S; Rogers CA; Abangma G; Raftery J; Harding SP; Lotery AJ; Downes SM; Chakravarthy U; Reeves BC;
BMJ Open; 2014 Jul; 4(7):e005094. PubMed ID: 25079928
[TBL] [Abstract][Full Text] [Related]
8. Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration.
Brown GC; Brown MM; Rapuano S; Boyer D
Am J Ophthalmol; 2020 Oct; 218():225-241. PubMed ID: 32565050
[TBL] [Abstract][Full Text] [Related]
9. A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer.
Goulart B; Ramsey S
Value Health; 2011; 14(6):836-45. PubMed ID: 21914503
[TBL] [Abstract][Full Text] [Related]
10. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness.
Raftery J; Clegg A; Jones J; Tan SC; Lotery A
Br J Ophthalmol; 2007 Sep; 91(9):1244-6. PubMed ID: 17431015
[TBL] [Abstract][Full Text] [Related]
11. Incremental cost-effectiveness of the pre- and post-bevacizumab eras of metastatic colorectal cancer therapy in British Columbia, Canada.
Hedden L; Kennecke H; Villa D; Johnston K; Speers C; Kovacic L; Renouf DJ; Peacock S
Eur J Cancer; 2012 Sep; 48(13):1969-76. PubMed ID: 22325838
[TBL] [Abstract][Full Text] [Related]
12. The Cost-Effectiveness of Ranibizumab for the Treatment of Diabetic Macular Edema.
Brown GC; Brown MM; Turpcu A; Rajput Y
Ophthalmology; 2015 Jul; 122(7):1416-25. PubMed ID: 25935787
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema.
Stein JD; Newman-Casey PA; Kim DD; Nwanyanwu KH; Johnson MW; Hutton DW
Ophthalmology; 2013 Sep; 120(9):1835-42. PubMed ID: 23642372
[TBL] [Abstract][Full Text] [Related]
14. [Cost-utility analysis of ranibizumab (Lucentis) in neovascular macular degeneration].
Neubauer AS; Holz FG; Schrader W; Back EI; Kühn T; Hirneiss C; Kampik A
Klin Monbl Augenheilkd; 2007 Sep; 224(9):727-32. PubMed ID: 17846963
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration.
Hernández-Pastor LJ; Ortega A; García-Layana A; Giráldez J
Graefes Arch Clin Exp Ophthalmol; 2010 Apr; 248(4):467-76. PubMed ID: 19669678
[TBL] [Abstract][Full Text] [Related]
16. The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters.
Elshout M; van der Reis MI; Webers CA; Schouten JS
Graefes Arch Clin Exp Ophthalmol; 2014 Dec; 252(12):1911-20. PubMed ID: 24777708
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of age-related macular degeneration in Greece.
Athanasakis K; Fragoulakis V; Tsiantou V; Masaoutis P; Maniadakis N; Kyriopoulos J
Clin Ther; 2012 Feb; 34(2):446-56. PubMed ID: 22289279
[TBL] [Abstract][Full Text] [Related]
18. Computerized model of cost-utility analysis for treatment of age-related macular degeneration.
Fletcher EC; Lade RJ; Adewoyin T; Chong NV
Ophthalmology; 2008 Dec; 115(12):2192-8. PubMed ID: 18930556
[TBL] [Abstract][Full Text] [Related]
19. A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer.
Montero AJ; Avancha K; Glück S; Lopes G
Breast Cancer Res Treat; 2012 Apr; 132(2):747-51. PubMed ID: 22200867
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov transition model.
Vottonen P; Kankaanpää E
Acta Ophthalmol; 2016 Nov; 94(7):652-656. PubMed ID: 27481048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
